CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Human Fetal Liver Cell Transplantationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01013194
NCT01013194Phase 2Completed
CompareCT.gov

Human Fetal Liver Cell Transplantation for Treatment of Chronic Liver Failure

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies·interventional·Posted Nov 13, 2009·Updated Nov 3, 2015

In Brief

A Phase 2 clinical trial evaluating Human Fetal Liver Cell Transplantation for Liver Cirrhosis. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The herein study consists in the transplantation of liver progenitor cells isolated from human fetal liver tissue with the aim of improving conventional liver therapy and broadening therapeutical options other than liver transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis
CountriesItaly
CollaboratorsUniversity of Pittsburgh

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 13, 2009
Enrollment StartFeb 1, 2007
Primary CompletionApr 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.6 years ago

Interventions

Human Fetal Liver Cell Transplantationother

Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation. Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance. Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2.